Clostridium difficile and inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 14, Issue 10, 2008, Pages 1432-1442

  Issa, Mazen ^a   Ananthakrishnan, Ashwin N ^a   Binion, David G ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

6 mercaptopurine; Azathioprine; Clostridium difficile; Colectomy; Crohn's disease; Enteritis; Fulminant colitis; Inflammatory bowel disease; Inflimab; Methotrexoate; Metronidazole; Nitazoxanide; Pseudomembranous colitis; Rifaximin; Ulcerative colitis; Vanocomycin

Indexed keywords

BACITRACIN; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; ENEMA; FUSIDIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; METRONIDAZOLE; NITAZOXANIDE; PREDNISONE; PROBIOTIC AGENT; PURINE DERIVATIVE; RIFAXIMIN; TEICOPLANIN; VANCOMYCIN;

BACTERIAL VIRULENCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLON RESECTION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FECES CULTURE; HAND WASHING; HOSPITAL HYGIENE; HOSPITALIZATION; HUMAN; ILEITIS; ILEOSTOMY; INFECTION PREVENTION; INFECTION RISK; INTESTINE RADIOGRAPHY; LACTOBACILLUS RHAMNOSUS; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROCTOCOLECTOMY; REVIEW; SACCHAROMYCES BOULARDII; SINGLE DRUG DOSE; TASTE DISORDER; ULCERATIVE COLITIS; CLOSTRIDIUM INFECTION; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROGNOSIS; RISK; RISK ASSESSMENT;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; COMORBIDITY; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 58849142243     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20500     Document Type: Review

References (142)

1. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.
2. Dallal RM, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235: 363-372.
3. Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983;18: 61-64.
4. Bolton RP, Sheriff RJ, Read AE. Clostridium difficile associated diarrhea; a role in inflammatory bowel disease? Lancet. 1980;i:383-384.
5. Trnka Y, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80:693-696.
6. Kressner MS, Williams SE, Biempica L, et al. Salmenonellosis complicating ulcerative colitis. Treatment with trimethoprime-sulfamethoxazole. JAMA. 1982;284:584-585.
7. Weber P, Koch M, Heizman WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol. 1992;14: 302-308.
8. Szilagui A, Gerson M, Mendelson J, et al. Salmonella infections complicating inflammatory bowel disease. J Clin Gastroenterol. 1985; 7:251-255.
9. Rampton DS, Salmon PR, Clark CG. Nonspecific colitis as a sequel to amebic dysentery. J Clin Gastroenterol. 1983;5:217-219.
10. Issa M, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345-351.
11. Rodemann JF, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.
12. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210.
13. Hall I, O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anerobe: Bacillus difficilis. Am J Dis Child. 1935;48:390-402.
14. [No authors listed.] Antibiotics, staphylococcal enteritis and pseudomembranous enterocolitis. N Engl J Med. 1953;249:37-40.
15. Tedesco FG, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med. 1974;81:429-433.
16. Bartlett JG, et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis. 1977;136:701-705.
17. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-415.
18. Muto CA, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273-280.
19. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
20. Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
21. Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1201-1205.
22. Songer JG, Anderson MA. Clostridium difficile: an important pathogen of food animals. Anaerobe. 2006;12:1-4.
23. Rodriguez-Palacios A, et al. Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis. 2007;13:485-487.
24. Issa M, et al. Decreasing rates of colectomy despite high rates of hospitalization in clostridium difficile infected IBD patients: a tertiary referral center experience. Gastroenterology. 2007;132:A663.
25. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22:848-856.
26. McFarland LV, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
27. Clabots CR, et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992;166:561-567.
28. McCoubrey J, et al. Clostridium difficile in a geriatric unit: a prospective epidemiological study employing a novel S-layer typing method. J Med Microbiol. 2003;52(Pt 7):573-578.
29. Wilcox MH, Fawley NW. Hospital disinfectants and spore formation by Clostridium difficile. Lancet. 2000;356:1324.
30. Underwood S, et al. Effects of hospital cleaning agents on spore formation by N American and UK outbreak Clostridium difficile strains. Am Soc Microbiol. 2005. Abstract LB28.
31. Akerlund T, et al. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol. 2006;44:353-358.
32. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18:247-263.
33. Hundsberger T, et al. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem. 1997;244: 735-742.
34. Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by Clostridium difficile. Infect Immun. 1981;34:1036-1043.
35. Lyerly DM, et al. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985;47:349-352.
36. Starr J. Clostridium difficile associated diarrhoea: diagnosis and treatment. BMJ. 2005;331:498-501.
37. Johnson S, et al. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med. 2001;135:434-438.
38. Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother. 1998;41(suppl C):13-19.
39. Bongaerts GP, Lyerly DM. Role of toxins A and B in the pathogenesis of Clostridium difficile disease. Microb Pathog. 1994;17:1-12.
40. Barbut F, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54(Pt 2):181-185.
41. Geric B, et al. Binary toxin-producing, large clostridial toxin-negative Clostridium dif.cile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis. 2006;193:1143-1150.
42. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
43. McEllistrem MC, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265-272.
44. Samore MH, et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium dif.cile diarrhea. Am J Med. 1996;100:32-40.
45. Leischner J, et al. Effect of alcohol hand gels and chlorhexidine hand wash in removing spores of Clostridium dif.cile from hands. American Society for Microbiology, 2005. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract LB29.
46. Gaynes R, et al. Outbreak of Clostridium difficile infection in a longterm care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640-645.
47. Mayfield JL, et al. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31:995-1000.
48. Wilcox MH, et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect. 2003;54:109-114.
49. Kyne L, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
50. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004;171:51-58.
51. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis. 2006;43:428-431.
52. Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. Postgrad Med J. 1987;63: 993-994.
53. Dial S, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-2995.
54. Dial S, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Cmaj. 2006;175:745-748.
55. Pepin J, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
56. Lowe DO, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43:1272-1276.
57. Arif M, et al. Patterns of proton pump inhibitor use in Inflammatory Bowel Disease and concomitant risk of Clostridium difficile infection. Gastroenterology. 2007;132:A516.
58. Bartlett JG, Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
59. Miller DL, Sedlack JD, Holt RW. Perforation complicating rifampin-associated pseudomembranous enteritis. Arch Surg. 1989;124:1082.
60. Jacobs A, et al. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2001;80:88-101.
61. Hayetian FD, et al. Ileal perforation secondary to Clostridium difficile enteritis: report of 2 cases. Arch Surg. 2006;141:97-99.
62. Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis Colon Rectum. 2000;43: 551-554.
63. Yee HF Jr, Brown RS Jr, Ostroff JW. Fatal Clostridium difficile enteritis after total abdominal colectomy. J Clin Gastroenterol. 1996; 22:45-47.
64. Kralovich KA, et al. Pseudomembranous colitis with associated fulminant ileitis in the defunctionalized limb of a jejunal-ileal bypass. Report of a case. Dis Colon Rectum. 1997;40:622-624.
65. Freiler JF, Durning SJ, Ender PT. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis. 2001;33: 1429-1431; discussion 1432.
66. Tsutaoka B, et al. Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Clin Infect Dis. 1994;18:982-984.
67. LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980;1:381-383.
68. Kuntz DP, et al. Clostridium difficile enteritis. A cause of intramural gas. Dig Dis Sci. 1993;38:1942-1944.
69. Tjandra JJ, et al. Fatal Clostridium difficile infection of the small bowel after complex colorectal surgery. ANZ J Surg. 2001;71:500-503.
70. Testore G, et al. Pseudomembranous enteritis associated with clostridium difficile. Italian Journal of Gastroenterology. 1984;16:229-230.
71. Shortland JR, Spencer RC, Williams JL. Pseudomembranous colitis associated with changes in an ileal conduit. J Clin Pathol. 1983;36: 1184-1187.
72. Lundeen SJ, et al. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg. 2007;11:138-142.
73. Mann SD, et al. Clostridium difficile infection-an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003;46:267-270.
74. Shen B, et al. Clostridium difficile-associated pouchitis. Dig Dis Sci. 2006;51:2361-2364.
75. Tsironi E, et al. "Diversion" colitis caused by Clostridium difficile infection: report of a case. Dis Colon Rectum. 2006; 49:1074-1077.
76. Guerrant RL, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32:331-351.
77. Gerding DN, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459-477.
78. Centers for Disease Control and Prevention (CDC). Frequently asked questions: information for healthcare providers [online]. 2006.
79. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2001;161:525-533.
80. Borek AP, Aird DZ, Carroll KC. Frequency of sample submission for optimal utilization of the cell culture cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol. 2005;43:2994-2995.
81. Ticehurst JR, et al. Effective detection of toxigenic Clostridium diffile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44:1145-1149.
82. Manabe YC, et al. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med. 1995;123:835-840.
83. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375-390.
84. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA. 1993;269:71-75.
85. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1-15.
86. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-822.
87. Teasley DG, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2:1043-1046.
88. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986;27:1169-1172.
89. Bricker E, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2005:CD004610.
90. Pepin J, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758-764.
91. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strian in Quebec. CMAJ. 2005;173:1037-1042.
92. Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile. N Engl J Med. 2006;354:1199-1203.
93. Musher DM, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40: 1586-1590.
94. Keighley MR, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J. 1978;2:1667-1669.
95. Mogg GA, et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl. 1980(suppl 22):41-45.
96. Young GP, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985;89:1038-1045.
97. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
98. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control. 1995;23:87-94.
99. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997; 92:739-750.
100. Olson MM, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol. 1994;15:371-381.
101. Kleinfeld DI, Sharpe RJ, Donta ST. Parenteral therapy for antibiotic-associated pseudomembranous colitis. J Infect Dis. 1988;157:389.
102. Oliva SL, et al. Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis. J Infect Dis. 1989;159:1154-1155.
103. Fekety R, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15-19.
104. Wenisch C, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813-818.
105. Zar FA, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307.
106. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995;36:673-679.
107. Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1982;77:220-221.
108. Parmar MS. Treating C. difficile. CMAJ. 2005;172:448; author reply 448.
109. Trudel JL, et al. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995;38:1033-1038.
110. Elinav E, Planer D, Gatt ME. Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis. Int J Colorectal Dis. 2004;19:273-276.
111. Burke GW, Wilson ME, Mehrez IO. Absence of diarrhea in toxic megacolon complicating Clostridium difficile pseudomembranous colitis. Am J Gastroenterol. 1988;83:304-307.
112. Dudley MN, et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986;146:1101-1104.
113. de Lalla F, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992;36:2192-2196.
114. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54:211-216.
115. Gerding DN, et al. In vitro activity of ramoplanin, rifalazil, rifaximin, metronidazole, and vancomycin against 110 unique toxigenic Clostridium difficile clinical isolates (abstract E-1439). American Society for Microbiology. Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005:171.
116. Boero M, et al. Treatment for colitis caused by Clostridium difficile: results of an open-label study of rifaximin vs. vancomycin. Microbiol Med. 1990;5:74.
117. Musher DM, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43:421-427.
118. Musher DM, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother. 2007;59:705-710.
119. Nair S, et al. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol. 1998;93:1873-1876.
120. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80:867-868.
121. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol. 2005;54(Pt 2):101-111.
122. Johnson S, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
123. Issa M, et al. Rifaximin and treatment of recurrent Clostridium difficile infection in patients with Inflammatory Bowel Disease. Am J Gastro. 2006;101:S469.
124. McPherson S, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640-645.
125. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;53:882-884.
126. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5:156-159.
127. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
128. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
129. Schwan A, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16:211-215.
130. Bowden TA Jr, Mansberger AR Jr, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg. 1981;47:178-183.
131. Synnott K, et al. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg. 1998;85:229-231.
132. Alfa MJ, Du T, Beda G. Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J Clin Microbiol. 1998;36:2076-2080.
133. Koss K, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149-154.
134. Haeck O, et al. Risk factors for mortality among patients with severe Clostridium difficile-associated diarrhea in two tertiary care hospitals in Quebec (2003-2004). American Society for Microbiology. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), 2005:327.
135. Lipsett PA, et al. Pseudomembranous colitis: a surgical disease? Surgery. 1994;116:491-496.
136. Medich DS, et al. Laparotomy for fulminant pseudomembranous colitis. Arch Surg. 1992;127:847-852; discussion 852-853.
137. Morris LL, Villalba MR, Glover JL. Management of pseudomembranous colitis. Am Surg. 1994;60:548-551; discussion 551-552.
138. Viswanath YK, Griffiths CD. The role of surgery in pseudomembranous enterocolitis. Postgrad Med J. 1998;74:216-219.
139. Mistry B, et al. Clostridium difficile colitis requiring subtotal colectomy in a renal transplant recipient: a case report and review of literature. Transplant Proc. 1998;30:3914.
140. Klipfel AA, et al. Acute abdomen and Clostridium difficile colitis: still a lethal combination. Dig Surg. 2000;17:160-163.
141. Zahariadis G, Connon JJ, Fong IW. Fulminant Clostridium difficile colitis without diarrhea: lack of emphasis in diagnostic guidelines. Am J Gastroenterol. 2002;97:2929-29230.
142. Grundfest-Broniatowski S, et al. Clostridium difficile colitis in the critically ill. Dis Colon Rectum. 1996;39:619-623.